Sorafenib in combination with intensive chemotherapy for previously untreated adult FLT3-Internal Tandem Duplication (FLT3-ITD) - positive AML: A Phase II randomised placebo-controlled multi-centre study evaluating two year progression-free survival
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2018
At a glance
- Drugs Sorafenib (Primary) ; Cytarabine; Etoposide; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Pharmacogenomic; Therapeutic Use
- 07 Aug 2018 Actual date last participant enrolled was 5/21/2018
- 07 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 22 May 2017 Status changed from not yet recruiting to recruiting.